share_log

礼来北京创新孵化器正式投入运营,首家合作企业签约入驻

Eli Lilly and Co's Peking Innovation Incubator officially begins Operation, and the first partner company has signed on.

Breakings ·  Mar 23 01:21

On March 22, Eli Lilly and Co announced that its first Innovative Drugs acceleration platform—Eli Lilly and Co Peking Innovation Incubator (Lilly Gateway Laboratory, LGL)—has officially started Operation. The Peking Innovation Incubator is dedicated to connecting resident companies with Eli Lilly and Co's professional science, management, and resource support to promote breakthroughs in the next generation of scientific innovation. The Peking Innovation Incubator is the fourth of its kind that Eli Lilly and Co has established globally, and this launch also marks the first time Eli Lilly and Co has expanded its Innovative Drugs incubation platform beyond the USA. The first tenant company of the Peking Innovation Incubator is Fubai Bio, which is registered in the Beijing Economic and Technological Development Zone and focuses on the research and development of Innovative Drugs for neurodegenerative diseases and other major nervous system diseases.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 385

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.